Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Geptanolimab in Alveolar Soft Part Sarcoma
NCT03623581Phase 2Unknown
- Sponsor
- Genor Biopharma
- Start
- Sep 2018
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of geptanolimab in alveolar soft part sarcoma (ASPS), sponsored by Genor Biopharma. Primary endpoint: Objective Response Rate up to 52 weeks. Status: unknown.
02
Drugs
geptanolimab
03
Conditions
alveolar soft part sarcoma (ASPS)
Beyond the preview
Go deeper on NCT03623581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03623581.